Abstract
In a bid to reduce the morbidity and mortality associated with coronary artery disease, statin therapy has become a cornerstone treatment for patients with dyslipideamia. Statins, or HMG-CoA reductase inhibitors, are effective in blocking hepatic synthesis of cholesterol and are generally regarded as safe. Although rare, severe adverse side effects such as rhabdomyolysis have been reported, however, the more common complaint from patients is that related to myopathy.
Original language | English |
---|---|
Pages (from-to) | 40-41 |
Number of pages | 2 |
Journal | Lipids in Health and Disease |
Volume | 11 |
DOIs | |
Publication status | Published - 2012 |
Externally published | Yes |